Related references
Note: Only part of the references are listed.Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
Ron T. Gansevoort et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease
Harpreet Bhutani et al.
KIDNEY INTERNATIONAL (2015)
Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure
Catriona Shaw et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial
Anna Caroli et al.
LANCET (2013)
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study
Piero Ruggenenti et al.
PLOS ONE (2012)
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Andreas L. Serra et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dose translation from animal to human studies revisited
Shannon Reagan-Shaw et al.
FASEB JOURNAL (2008)
Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease
Baoxue Yang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Autosomal dominant polycystic kidney disease
Jared J. Grantham
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease
JM Shillingford et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (Withdrawn paper, art. no. CD002967, 2006)
S Salpeter et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2006)
Obesity, proteinuria and progression of renal failure
Manuel Praga et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2006)
Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes
Jared J. Grantham et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
The relationship between cell proliferation, Cl- secretion, and renal cyst growth:: A study using CFTR inhibitors
HY Li et al.
KIDNEY INTERNATIONAL (2004)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase
KR Hallows et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
